|
JUNE 18, 2025
FDA Approves Yeztugo for HIV PrEP Lasting 6 Months
By IDSE News Staf
The FDA approved lenacapavir (Yeztugo, Gilead Sciences), an injectable HIV-1 capsid inhibitor, to be used as pre-exposure prophylaxis (PrEP) to reduce the risk for sexually acquired HIV in adults and adolescents weighing at least 35 kg, making it the first and only twice-yearly option for Americans who need or want PrEP.
Data show that almost 100% of participants who received lenacapavir in the phase 3 PURPOSE 1 and PURPOSE 2 trials remained HIV-negative. These trials supported the FDA’s approval.
In the PURPOSE 1 trial (ClinicalTrials.gov Identifier: NCT04994509), data at the primary analysis showed twice-yearly subcutaneous lenacapavir demonstrated zero HIV infections among 2,134 participants in the lenacapavir group, 100% reduction in HIV infections and superiority of prevention of HIV infections when compared with once-daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF; Truvada, Gilead) in cisgender women in sub-Saharan Africa.
In the PURPOSE 2 trial (NCT04925752), there were two HIV infections among 2,179 participants in the twice-yearly subcutaneous lenacapavir group, demonstrating 99.9% of patients in the lenacapavir group did not acquire HIV infection and superiority of prevention of HIV infections when compared with once-daily oral F/TDF among a broad and geographically diverse range of cisgender men and gender-diverse people. In both trials, lenacapavir also demonstrated superiority in preventing HIV infections when compared with background HIV incidence and was generally well tolerated, with no significant or new safety concerns identified.
In 2022, only about 1 in 3 (36%) people in the United States who were eligible for PrEP were prescribed a form of it. CDC data show that all populations in the United States are not yet using PrEP at rates that could end transmission of the virus at the population level, with particular gaps for women, Black and Hispanic/Latino people, and those in the South. Data also show that barriers including adherence challenges, stigma and low awareness of existing PrEP options—by both healthcare providers and consumers—contribute to this low uptake of PrEP across multiple populations (J Acquir Immune Defic Syndr 2018;77[2]:119-127).
The potential effect of this limited uptake, adherence and access is underscored by the fact that, in 2023, more than 100 people were diagnosed with HIV every day in the United States.
Continue reading... https://www.idse.net/FDA-News/Article/06-25/Yeztugo-FDA-Approved-HIV-PrEP/77487
CONTACT
Marie Rosenthal
MRosenthal@McMahonmed.com
"Reproduced with permission - Infectious Disease Special Edition (IDSE)"
Infectious Disease Special Edition (IDSE)
Back to ...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS: HIV/AIDS News Archive
|
